Thiol-Activated HNO Release from a Ruthenium Antiangiogenesis Complex and HIF-1α Inhibition for Cancer Therapy

[Image: see text] Metallonitrosyl complexes are promising as nitric oxide (NO) donors for the treatment of cardiovascular, endothelial, and pathogenic diseases, as well as cancer. Recently, the reduced form of NO(–) (protonated as HNO, nitroxyl, azanone, isoelectronic with O(2)) has also emerged as...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva Sousa, Eduardo Henrique, Ridnour, Lisa A., Gouveia, Florêncio S., Silva da Silva, Carlos Daniel, Wink, David A., de França Lopes, Luiz Gonzaga, Sadler, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2016
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949585/
https://www.ncbi.nlm.nih.gov/pubmed/27191177
http://dx.doi.org/10.1021/acschembio.6b00222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949585/
https://www.ncbi.nlm.nih.gov/pubmed/27191177
http://dx.doi.org/10.1021/acschembio.6b00222

Ejemplares similares